Overview of the therapeutic potential of piplartine (piperlongumine)

• Published in: European journal of pharmaceutical sciences Vol. 48; no. 3; pp. 453 - 463
• Main Authors: Bezerra, Daniel P., Pessoa, Claudia, de Moraes, Manoel O., Saker-Neto, Nicolau, Silveira, Edilberto R., Costa-Lotufo, Leticia V.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 14.02.2013
• Subjects: Animals; Anticancer activity; Antineoplastic Agents, Phytogenic - metabolism; Antineoplastic Agents, Phytogenic - pharmacokinetics; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Ayurvedic medicine; Biological Availability; Drugs, Investigational - metabolism; Drugs, Investigational - pharmacokinetics; Drugs, Investigational - pharmacology; Drugs, Investigational - therapeutic use; Fruit - chemistry; Humans; Long pepper; Medicine, Ayurvedic; Neoplasms - drug therapy; Neoplasms - metabolism; Patents as Topic; Piper - chemistry; Piperaceae; Piperidones - metabolism; Piperidones - pharmacokinetics; Piperidones - pharmacology; Piperidones - therapeutic use; Piperlongumine; Piplartine; CDKN1A; Anticancer activity; ALT; HDRA; p53; UV–vis; NF-κB; Ayurvedic medicine; Piplartine; CBR1; GSTO1; MS; RPS5; ANXA5; 1H NMR; IR; Survivin; Noxa; ERK1/2; ROS; Bcl-2; Long pepper; AHNAK; GLO1; GSTP1; CNS; XIAP; PARP; TLC; MMTV-PyVT; Twist; p120ctn; HIF-2; Rf; ΔΨm; PRDX1; CDIP; PMBC; CD31; GSTM3; Piperlongumine; AST; VEGF; Bim; Piperaceae; SILAC; GSTZ1; Raf; Cdk2; Cdc-2; PLEKHM1; VIM; PUMA; 5-FU; PDGF-BB
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/j.ejps.2012.12.003

Piplartine (piperlongumine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone) is a biologically active alkaloid/amide from peppers, as from long pepper (Piper longum L. – Piperaceae). Long pepper is one of the most widely used in Ayurvedic medicine, which is used to treat many diseases, including tumors. The purpose of the current paper is to address to the chemical structure establishment and to systematically survey the published articles and highlight recent advances in the knowledge of the therapeutic potential of piplartine, establishing new goals for future research. The reported pharmacological activities of piplartine include cytotoxic, genotoxic, antitumor, antiangiogenic, antimetastatic, antiplatelet aggregation, antinociceptive, anxiolytic, antidepressant, anti-atherosclerotic, antidiabetic, antibacterial, antifungal, leishmanicidal, trypanocidal, and schistosomicidal activities. Among the multiple pharmacological effects of piplartine, its anticancer property is the most promising. Therefore, the preclinical anticancer potential of piplartine has been extensively investigated, which recently resulted in one patent. This compound is selectively cytotoxic against cancer cells by induction of oxidative stress, induces genotoxicity, as an alternative strategy to killing tumor cells, has excellent oral bioavailability in mice, inhibits tumor growth in mice, and presents only weak systemic toxicity. In summary, we conclude that piplartine is effective for use in cancer therapy and its safety using chronic toxicological studies should be addressed to support the viability of clinical trials.